To date, three ICIs have been approved by the US Food and Drug Administration for the treatment of CRC, including the monoclonal antibodies pembrolizumab and nivolumab, which target PD-1, and ipilimumab, which targets CTLA-4 (47). The gene discussed is CTLA4; the disease is colorectal carcinoma.